Videos

Dr Mary Mulcahy, an expert oncologist, details how radioembolization is involved in the treatment of colorectal cancer with liver metastasis.

Mark J. Roschewski, MD, discusses standard of care options for the treatment of follicular lymphoma.

Nino Balanchivadze, MD, FACP, discusses the results of an analysis investigating renal toxicity in patients with nonsquamous non–small cell lung cancer in relation to the race of patients.

Catherine Callaghan Coombs, MD, discusses the mechanism of action of pirtobrutinib in chronic lymphocytic leukemia and small lymphocytic leukemia.

Sarah P. Psutka, MD, discusses the key findings of a retrospective study of the efficacy of Immune checkpoint inhibitor plus tyrosine kinase inhibitor as any-line treatment for patients with renal cell carcinoma.

Mary F. Mulcahy, MD, describes the treatment options available for colorectal cancer with liver metastasis in the first and second line.

Alice S. Mims, MD, Acute Leukemia Clinical Research director and associate professor in the Division of Hematology at Ohio State University Comprehensive Cancer Center, discusses key updates to the National Comprehensive Cancer Network guidelines on newly-diagnosed acute myeloid leukemia.

Catherine Callaghan Coombs, MD, discusses 2 upcoming trials in chronic lymphocytic leukemia.

Tom Hutson, DO, PharmD, reviews the case of a 59-year-old woman with metastatic renal cell carcinoma, with intermediate risk and the role of risk assessment in patient management.

Drs Michael Bishop and John DiPersio comment on common challenges in measuring response in chronic GvHD and review clinical implication from the REACH3 trial.

A discussion of standard frontline treatment approaches and considerations for utilizing maintenance therapy for patients with germinal center B-cell and activated B-cell subtypes of diffuse large B-cell lymphoma.

A review of the criteria that help hematologist-oncologists appropriately manage patients with diffuse large B-cell lymphoma.

Experts in hematology/oncology review factors to consider when approaching the management of chronic graft-versus-host disease.

Mazyar Shadman, MD, MPH, and Jonathon Cohen, MD, MS, discuss possible future developments with BTKi as therapy options in B-cell lymphomas.

Drs Shadman and Cohen introduce new data concerning a third-generation BTK inhibitor, pirtobrutinib, and discuss unmet needs in the B-cell malignancy landscape.

Jason Westin, MD, discusses the future of diffuse large B-cell lymphoma treatment.

Guiseppe Curigliano, MD, discusses the rationale behind a subgroup HER2CLIMB study, which evaluated the efficacy and safety of tucatinib in combination with trastuzumab and capecitabine in pretreated HER2-positive breast cancer patients with and without brain metastases compared with placebo.

Irene Ghobrial, MD discusses multiple trials and their significance for treating patients with smoldering multiple myeloma and newly diagnosed multiple myeloma.

Neeraj Agarwal, MD, discusses the PSA response rate and adherence rate of a real-world study of apalutamide in patients with prostate cancer across 63 United States urology practices.

Erika P. Hamilton, MD, discusses unmet needs in treatment options for platinum-resistant ovarian cancer due to the challenges of screening, and what treatment options may become viable in the future.

John DiPersio, MD, PhD, and Michael Bishop, MD, discuss third-line treatment options for patients with acute and steroid-refractory GVHD.

John DiPersio, MD, PhD, shares his thoughts on approaching initial therapy for chronic GVHD and early intervention with JAK inhibitors.

Mazyar Shadman, MD, MPH, and Jonathon Cohen, MD, MS, share their preferences regarding BTK-targeted treatment in B-cell malignancies.

Two experts discuss use of ibrutinib and zanubrutinib and data from the ALPINE and ELEVATE-RR trials.

Michael Wang, MD, discusses the real-world efficacy of brexucabtagene autoleucel, the first chimeric antigen receptor T-cell therapy for the treatment of mantle cell lymphoma.

Scott T. Tagawa, MD, FACP, shares clinical pearls and advice for the management of mCRPC.

An expert in prostate cancer comments on emerging agents and combinations in the pipeline for the treatment of mCRPC.

Scott T. Tagawa, MD, FACP, shares his thoughts on remaining questions for imaging and PSMA-targeted therapy for mCRPC.

Dr Scott T. Tagawa discusses common adverse events associated with 177Lu-PSMA-617 in patients with mCRPC and how to appropriately manage them.

A prostate cancer expert considers clinical implications from the phase 3 VISION study, including the potential role of 177Lu-PSMA-617 therapy for patients with mCRPC.